235 related articles for article (PubMed ID: 35243413)
1. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Freeman SS; Sade-Feldman M; Kim J; Stewart C; Gonye ALK; Ravi A; Arniella MB; Gushterova I; LaSalle TJ; Blaum EM; Yizhak K; Frederick DT; Sharova T; Leshchiner I; Elagina L; Spiro OG; Livitz D; Rosebrock D; Aguet F; Carrot-Zhang J; Ha G; Lin Z; Chen JH; Barzily-Rokni M; Hammond MR; Vitzthum von Eckstaedt HC; Blackmon SM; Jiao YJ; Gabriel S; Lawrence DP; Duncan LM; Stemmer-Rachamimov AO; Wargo JA; Flaherty KT; Sullivan RJ; Boland GM; Meyerson M; Getz G; Hacohen N
Cell Rep Med; 2022 Feb; 3(2):100500. PubMed ID: 35243413
[TBL] [Abstract][Full Text] [Related]
2. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
4. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
6. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
[TBL] [Abstract][Full Text] [Related]
7. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.
Georgoulias G; Zaravinos A
Front Immunol; 2022; 13():1006665. PubMed ID: 36389735
[TBL] [Abstract][Full Text] [Related]
12. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
[TBL] [Abstract][Full Text] [Related]
13. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
[TBL] [Abstract][Full Text] [Related]
14. Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival.
Gao Y; Yang C; He N; Zhao G; Wang J; Yang Y
Front Oncol; 2020; 10():571545. PubMed ID: 33194669
[TBL] [Abstract][Full Text] [Related]
15. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
Lu M; Wu KH; Trudeau S; Jiang M; Zhao J; Fan E
Sci Rep; 2020 Nov; 10(1):20575. PubMed ID: 33239757
[TBL] [Abstract][Full Text] [Related]
16. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
[TBL] [Abstract][Full Text] [Related]
18. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
19. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
20. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]